Hepatitis C Articles (HCV)
Back
	Sovaldi studies Child-Pugh B Cirrhosis/Advanced Liver Disease/Post-Transplant       Sofosbuvir/GS-5816 Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis   Sofosbuvir/GS-5816 Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis (ASTRAL-4) phase 3   This study is currently recruiting participants. (see Contacts and Locations) Verified August 2014 by Gilead Sciences   This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) with and without ribavirin (RBV) for 12 weeks and SOF/GS-5816 FDC for 24 weeks in adults with hepatitis C virus (HCV) infection and Child-Pugh (CPT) class B cirrhosis.   --------------------------   Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant   Participants with cirrhosis and moderate hepatic impairment (CPT Class B) will be randomized to receive either 12 or 24 weeks of LDV/SOF FDC plus RBV. Participants with cirrhosis and severe hepatic impairment (CPT Class C) will be randomized to receive either 12 or 24 weeks of LDV/SOF FDC plus RBV.           View Older Articles   Back to Top   www.natap.org